- Immuron Limited has increased the amount available for sale under its At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC.  **[1660046_0001213900-25-095881_ea0260180-6k_immuron.htm:1]** 
- The company may now offer and sell an **additional aggregate offering price of up to $2,847,954** in American Depositary Shares (ADSs).  **[1660046_0001213900-25-095881_ea0260180-6k_immuron.htm:1]** **[1660046_0001213900-25-095881_ea026018001ex5-1_immuron.htm:1]** 
- This increase is effective as of **October 3, 2025**, and is separate from the **$2,068,866 of securities already sold** under the program in the 12-calendar month period ending on that date.  **[1660046_0001213900-25-095881_ea0260180-6k_immuron.htm:1]** 
- Each ADS is convertible into **40 fully paid ordinary shares**.  **[1660046_0001213900-25-095881_ea026018001ex5-1_immuron.htm:1]**

Immuron Increases At-The-Market Offering Capacity

- Immuron Limited reported **FY25 Global Sales Revenue of A$7.3 million**, marking a **49% increase** year-over-year, driven by **North American Travelan® sales which grew 76% to A$2.0 million**.  **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:3]** **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:4]** 
- As of June 30, 2025, the company held **A$5.9 million in cash and term deposits**, with an additional A$2.8 million raised in July 2025.  **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:3]** **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:4]** 
- Key upcoming clinical milestones include the anticipated release of **topline data for the Travelan® (IMM-124E) Uniformed Services University trial in October 2025** and the **submission of an FDA IND for IMM-529 by September 30, 2025**, with approval expected by **December 31, 2025**.  **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:3]** **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:5]**  
- The Australian launch of **ProIBS® is planned for Q1 CY2026**.  **[1660046_0001213900-25-087898_ea025750901ex99-1_immu.htm:3]**

Immuron Ltd. Reports Strong FY25 Sales Growth and Outlines Key Clinical Milestones

- Immuron Limited reported a **48.6% increase** in revenue from ordinary activities, reaching **$7,287,002** for the year ended June 30, 2025, primarily driven by Travelan® sales in Australia and North America.  **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:0]** **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:1]** 
- The company's loss after tax decreased by **24.3%** to **($5,253,209)** for the year ended June 30, 2025, compared to ($6,936,957) in the prior year.  **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:0]** **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:1]** 
- Cash and cash equivalents significantly declined to **$2,830,526** as of June 30, 2025, down from $11,657,315 at June 30, 2024.  **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:0]** **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:1]** 
- Post-reporting period, in July 2025, Immuron Limited raised gross proceeds of **USD$1,822,322 (AUD$2,809,177)** through an At The Market Facility.  **[1660046_0001213900-25-082922_ea025525501ex99-1_immuron.htm:7]**

Immuron Limited Announces Preliminary FY25 Financial Results

- Immuron Limited announced on **August 26, 2025**, a partnership with **InvestorHub** to launch an interactive investor hub, aiming to improve communication with investors and stakeholders.  **[1660046_0001213900-25-080490_ea0254587-6k_immuron.htm:0]** **[1660046_0001213900-25-080490_ea025458701ex99-2_immuron.htm:0]** 
- The company plans to regularly upload new content to the hub, including videos, educational material, interviews, and corporate research.  **[1660046_0001213900-25-080490_ea025458701ex99-2_immuron.htm:0]** 
- Immuron's CEO, Steven Lydeamore, highlighted anticipated near-term milestones for the remainder of the calendar year, including the **submission and FDA approval of IMM-529 Investigational New Drug (IND) submission** and the release of **topline results from the Travelan® (IMM-124E) clinical trial**.  **[1660046_0001213900-25-080490_ea025458701ex99-2_immuron.htm:0]**

Immuron (IMRN)